1.
Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers
by Wallis, Robert S, Prof
The Lancet infectious diseases, 2016, Vol.16 (4), p.e34-e46
2.
Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial
by Ruslami, Rovina, PhD
The Lancet infectious diseases, 2013, Vol.13 (1), p.27-35
3.
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis
by Caminero, José A, Dr
The Lancet infectious diseases, 2010, Vol.10 (9), p.621-629
4.
The association between sterilizing activity and drug distribution into tuberculosis lesions
by Prideaux, Brendan
Nature medicine, 2015, Vol.21 (10), p.1223-1227
5.
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action
by Sacksteder, Katherine A
Future microbiology, 2012, Vol.7 (7), p.823-837
6.
Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux
by Lee, Richard E
Nature medicine, 2014, Vol.20 (2), p.152-158
7.
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
by Imperial, Marjorie Z
Nature medicine, 2018, Vol.24 (11), p.1708-1715
8.
The number of privately treated tuberculosis cases in India: an estimation from drug sales data
by Arinaminpathy, Nimalan, Dr
The Lancet infectious diseases, 2016, Vol.16 (11), p.1255-1260
9.
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
by Zumla, Alimuddin I, Prof
The Lancet infectious diseases, 2014, Vol.14 (4), p.327-340
10.
International Standards for Tuberculosis Care
by Hopewell, Philip C
The Lancet infectious diseases, 2006, Vol.6 (11), p.710-725
11.
Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy
by Li, Feng
Nature medicine, 2013, Vol.19 (4), p.418-420
12.
Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions
by Ordonez, Alvaro A
Nature medicine, 2020, Vol.26 (4), p.529-534
13.
Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis
by Ettehad, Dena, BSc
The Lancet infectious diseases, 2012, Vol.12 (6), p.449-456
14.
Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study
by Walker, Timothy M, Dr
The Lancet infectious diseases, 2015, Vol.15 (10), p.1193-1202
15.
Tuberculosis: advances and challenges in development of new diagnostics and biomarkers
by Walzl, Gerhard
The Lancet infectious diseases, 2018, Vol.18 (7), p.e199-e210
16.
Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis
by Gegia, Medea, MD
The Lancet infectious diseases, 2016, Vol.17 (2), p.223-234
17.
The magic bullets and tuberculosis drug targets
by Zhang, Ying
Annual review of pharmacology and toxicology, 2005, Vol.45 (1), p.529-564
18.
Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives
by Gygli, Sebastian M
FEMS microbiology reviews, 2017, Vol.41 (3), p.354-373
19.
Global burden of drug-resistant tuberculosis in children: a mathematical modelling study
by Dodd, Peter J, Dr
The Lancet infectious diseases, 2016, Vol.16 (10), p.1193-1201
20.
Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index
by Wasserman, Sean
Expert review of anti-infective therapy, 2016, Vol.14 (10), p.901-915
